@article{7073cfbc4d6b4673abd60148b5a0fb33,
title = "Repurposing the dual orexin receptor antagonist suvorexant for the treatment of opioid use disorder: why sleep on this any longer?",
author = "James, {Morgan H.} and Fragale, {Jennifer E.} and Aurora, {R. Nisha} and Cooperman, {Nina A.} and Langleben, {Daniel D.} and Gary Aston-Jones",
note = "Funding Information: MHJ is supported by National Institute on Drug Abuse (NIDA; K99DA045765). JEF is supported by the National Institutes of Health (NIH) IRACDA postdoctoral fellowship (K12 GM093854). RNA is supported by the National Heart, Lung and Blood Institute (HL118414). NAC is supported by NCCIH and NIDA (R33 AT010109) and a Laura and Arnold Foundation Grant. DDL is supported by NIDA (R21 DA043983). GAJ is supported by NIDA (R01 DA006214). RNA is on the Board of Directors for the American Academy of Sleep Medicine, The American Academy of Sleep Medicine— Foundation, and the American Board of Sleep Medicine. DDL served on the Scientific Advisory Board of Alkermes Inc and US WorldMeds. GAJ has been a consultant for Merck Pharmaceuticals. All other authors have no disclosures to report.",
year = "2020",
month = apr,
day = "1",
doi = "10.1038/s41386-020-0619-x",
language = "English (US)",
volume = "45",
pages = "717--719",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "5",
}